Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients An open, pilot study

Blood Pressure

Volumn 19, Issue 4, 2010, Pages 260-266

  Kuklinska, Agnieszka M ^a   Mroczko, Barbara ^a   Musial, Wlodzimierz J ^a   Sawicki, Robert ^a   Kozieradzka, Anna ^a   Usowicz Szarynska, Monika ^a   Kaminski, Karol ^a   Knapp, Malgorzata ^a   Szmitkowski, MacIej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Arterial hypertension; Atorvastatin; Nitric oxide; Oxidized low density lipoprotein; Prostacyclin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOGLOBULIN G ANTIBODY; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROSTACYCLIN;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; PYRROLES; TRIGLYCERIDES;

EID: 77952137168     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037050903576726     Document Type: Article

References (22)

1. Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J. 2009;73:595-601.
2. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep. 2008;60:3-11.
3. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60.
4. Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosioni E. Statins and blood pressure regulation. Curr Hypertens Rep. 2001;3:281-288.
5. Tesfamariam B. The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs. 2006; 6:115-120.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
7. Milionis HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP. Statins: Another class of antihypertensive agents? J Hum Hypertens. 2006;20:320-335.
8. Ge CJ, Hu SJ, Wu YS, Chen NY. Effects of atorvastatin on vascular remodeling in spontaneously hypertensive rats. J Zhejiang Univ Sci. 2003;4:612-615.
9. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduc tion lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;20: 1020-1025.
10. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000;35:549-555.
11. Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol. 1995;48:217-223.
12. Spósito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83: 1497-1499, A8.
13. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1286.
14. ODriscoll G, Green D, Taylor RR. Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
15. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
16. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999;33:234-241.
17. Zhou MS, Schulman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibrinogen with concomitant increase in nitric oxide bioavialability. Am J Physiol Renal Physiol. 2008; 295:F53-F59.
18. de Sotomayor MA, Pérez-Guerrero C, Herrera MD, Jimenez L, Marín R, Marhuenda E, et al. Improvement of age-related endothelial dysfunction by simvastatin: Effect on NO and COX pathways. Br J Pharmacol. 2005;146:1130-1138.
19. OMeara SJ, Kinsella BT. Effect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo. Br J Pharmacol. 2004;143:292-302.
20. Martínez-González J, Escudero I, Badimon L. Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: Effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis. 2004;174: 305-313.
21. Bayorn MA, Layas MF, Mann G, Feuerstein GZ, Eatman D. The effect of diet on simvastatin and losartan enhancement of endothelial function. Clin Exp Hypertens. 2007;29:311-325.
22. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al.; ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.Eur Heart J. 2006;27:2982-2988.